Literature DB >> 18085709

Post-neonatal drop in alveolar SP-A expression: biological significance for increased vulnerability to SIDS?

Arne Stray-Pedersen1, Ashild Vege, Asbjorg Stray-Pedersen, Uffe Holmskov, Torleiv Ole Rognum.   

Abstract

BACKGROUND: Surfactant protein A (SP-A) is synthesized in the lung and is a part of the innate immune system. The aim of this study was to evaluate the expression of SP-A in lung tissue from fetuses, infants, children and adults with special regard to sudden infant death syndrome (SIDS).
METHODS: A total of 160 cases were studied; 19 fetuses and neonates, 59 SIDS and 49 explained infant deaths below 1 year of age, 19 toddlers and 14 adults. Immunohistochemical detection of SP-A using monoclonal antibodies was performed by microscopy of lung tissue specimens collected at autopsy. A scoring system was developed enabling semi-quantitative estimation of staining intensity and distribution.
RESULTS: SP-A was detected in the terminal bronchioles and alveolar spaces of fetuses >35 weeks gestation. The intra-alveolar SP-A expression increased in the perinatal period followed by a marked drop in infants aged between 1 week and 5 months. Infants aged >5 months had abundant SP-A expression corresponding to older children and adults. There was no difference in the age distribution between cases of SIDS and explained deaths.
CONCLUSIONS: The apparent drop in SP-A expression takes place in the first months after birth, corresponding with the classical age peak of SIDS. We therefore hypothesize that low expression of SP-A may be related in some as-yet undetermined way to the increased risk of SIDS at that age. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085709     DOI: 10.1002/ppul.20750

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  1 in total

Review 1.  Sudden infant death syndrome and the genetics of inflammation.

Authors:  Linda Ferrante; Siri Hauge Opdal
Journal:  Front Immunol       Date:  2015-02-20       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.